Tenaya Therapeutics has secured substantial capital through multiple financing rounds, including major venture capital preferred stock issuances, private placements, and its initial public offering on the NASDAQ stock exchange. Additionally, the biopharmaceutical company has supplemented its balance sheet through strategic research collaborations and institutional funding designed to advance its pipeline of heart disease therapeutics.